Drägerwerk stock weighs stronger sales against Q3 margin pressure

Drägerwerk reported stronger sales and earnings for the first nine months of 2026 on October 29, but the third quarter showed renewed pressure on profitability. The company kept its full-year outlook unchanged, according to the Deutsche Börse.

Stronger Sales Across Both Divisions

Currency-adjusted order intake increased 3.6 percent to EUR 2,673.5 million in the first nine months, while currency-adjusted net sales rose 5.3 percent to EUR 2,453.9 million. Medical Technology sales increased 4.4 percent to EUR 1,367.0 million, and Safety Technology sales climbed 6.5 percent to EUR 1,087.0 million.

Order intake in Safety Technology was a key growth driver, rising 13.1 percent on a currency-adjusted basis. Medical Technology order intake fell 3.5 percent, although the company said the comparison was affected by a major hospital infrastructure order received in the prior year. Regional demand increased in Germany, EMEA and Asia-Pacific, while the Americas declined against a high prior-year base.

Quarterly Profitability Remains In Focus

Third-quarter order intake rose 7.0 percent to EUR 926.2 million, and sales increased 1.0 percent on a currency-adjusted basis to EUR 850.8 million. EBIT, however, fell to EUR 48.0 million from EUR 56.7 million a year earlier, reducing the EBIT margin to 5.6 percent from 6.8 percent.

For the first nine months, EBIT increased to EUR 111.8 million from EUR 77.1 million and the margin improved to 4.6 percent from 3.3 percent. The result included EUR 27.9 million in customs refunds, including EUR 20.1 million in the third quarter. The company also reported EUR 25.8 million in U.S. customs expenses incurred during 2026 that are nonrefundable under current law. Personnel, logistics and IT costs lifted functional expenses by 5.6 percent in the first nine months.

Outlook Holds Despite Q3 Weakness

Dräger continues to target currency-adjusted sales growth of 2.0 to 6.0 percent and an EBIT margin of 6.0 to 8.0 percent for 2026. For investors, the stronger order intake and Safety Technology performance support the revenue case, while the lower quarterly margin leaves cost control and execution in the final quarter central to the earnings target.

Drägerwerk stock traded at 102.50 euros on Lang & Schwarz at 10:35 CET on Monday, November 9, 2026, 0.68 percent below the Xetra close of Friday, November 6. Investors can follow the real-time quote of Drägerwerk stock.

The broader German market is represented by the DAX.

More news and analyses on Drägerwerk stock